AdAlta Ltd (ASX:1AD) CEO Tim Oldham tells Proactives Elisha Newell that new data on lead drug candidate AD-214 favourably links preclinical animal studies and Phase I human trial results, providing important dose frequency insights as it moves through the clinic. The findings de-risk the I-body candidates future move into Phase 2 clinical trials and stand to boost confidence as AdAlta progresses partnership discussions. Oldham says the new data is critically important and a credit to AdAltas in-house scientific team.
+61 413 713 744
View source version on newsdirect.com: https://newsdirect.com/news/adalta-links-ad-214-results-with-efficacy-thanks-to-new-data-242490503